J&J's Pasritamig Prostate Cancer Combo Shows Early Promise, But Core Risks Persist

What happened

Johnson & Johnson announced Phase 1 data for pasritamig in combination with JNJ-9401 in advanced prostate cancer, showing a 73% PSA response rate (11 of 15 patients) and deep responses with every-six-week dosing. The data are early and from a small trial, but suggest potential for a novel dual-antigen-targeted immunotherapy with outpatient dosing as it moves to Phase 3. The DeepValue report rates J&J a WAIT with conviction 3.5, acknowledging the company's diversified pipeline but focusing on near-term risks including STELARA biosimilar erosion (already down 59.7% YoY in Q1 FY2026) and the CVS formulary switch effective July 1, 2026. Talc litigation remains an unbounded overhang with ~75,000 plaintiffs and a $3.4B reserve, and management cannot estimate losses beyond accruals. While the pasritamig news is a positive pipeline signal, it does not alter the current valuation or the asymmetric downside from payer and legal events over the next 3-6 months.

Implication

Investors should treat the pasritamig data as a minor positive that adds optionality to J&J's oncology portfolio, but should not re-rate the stock until Phase 3 results confirm efficacy and safety in larger populations. The core investment debate remains the pace of STELARA erosion post-CVS formulary change and the trajectory of talc litigation, both of which are discrete catalysts over the next quarter. The report's base case values J&J at $235, with a bear case $190 and bull $265, implying current price $228 is near fair value but with skewed downside risk. A more attractive entry would be near $200, where the risk/reward improves if immunology deterioration accelerates or legal headlines worsen. Conversely, confirmation of immunology stabilization and bounded talc exposure in Q2-Q3 FY2026 would support an upgrade to a more constructive stance.

Thesis delta

The release of promising Phase 1 data for pasritamig/JNJ-9401 does not change the WAIT rating or the primary thesis drivers. It adds a marginal incremental positive to the pipeline narrative but is too early-stage to offset the near-term headwinds from STELARA erosion and litigation uncertainty. The thesis remains anchored on awaiting Q2-Q3 FY2026 proof of immunology stabilization and bounded talc exposure.